Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples